度拉糖肽与2型糖尿病肾脏结局:REWIND随机安慰剂对照试验的探索性分析
REWIND为多中心、随机、双盲、安慰剂对照试验,在24个国家371个中心纳入9901例年龄≥50岁、有既往心血管事件或心血管危险因素的2型糖尿病患者,1:1随机接受每周皮下注射度拉糖肽1.5 mg或安慰剂。中位随访5.4年(IQR 5.1-5.9),度拉糖肽组848例(17.1%)发生复合肾脏结局,发生率为3.5/100人年;安慰剂组970例(19.6%),发生率为4.1/100人年(HR 0.85,95%CI 0.77-0.93;p=0.0004)。效应最明显的是新发大量白蛋白尿(HR 0.77,95%CI 0.68-0.87;p<0.0001)。作者结论为长期使用度拉糖肽与2型糖尿病患者复合肾脏结局减少相关。
要点
- 在2型糖尿病合并心血管病史或心血管危险因素人群中,度拉糖肽组复合肾脏结局发生率为3.5/100人年,安慰剂组为4.1/100人年(HR 0.85,95%CI 0.77-0.93;p=0.0004)。
- 新发大量白蛋白尿(尿白蛋白与肌酐比值>33.9 mg/mmol)的效应最明显:度拉糖肽相比安慰剂HR 0.77(95%CI 0.68-0.87;p<0.0001)。
- 估算肾小球滤过率持续下降≥30%的HR为0.89(95%CI 0.78-1.01;p=0.066),未达统计学显著。
- 慢性肾脏替代治疗的HR为0.75(95%CI 0.39-1.44;p=0.39),未达统计学显著。
- 给药方案为每周皮下注射度拉糖肽1.5 mg,对照为安慰剂,中位随访5.4年(IQR 5.1-5.9);尿白蛋白与肌酐比值、估算肾小球滤过率每12个月检测一次。
适用人群与场景
- 年龄≥50岁的2型糖尿病男性与女性,且有既往心血管事件或心血管危险因素;纳入REWIND试验并随机分入度拉糖肽组或安慰剂组。
- 基线时791例(7.9%)存在大量白蛋白尿,平均估算肾小球滤过率为76.9 mL/min/1.73 m²(SD 22.7)。
诊断标准与关键阈值
- 复合肾脏结局定义为以下任一事件首次发生:新发大量白蛋白尿(尿白蛋白与肌酐比值>33.9 mg/mmol)、估算肾小球滤过率较基线持续下降≥30%、或开始慢性肾脏替代治疗。
处置流程与药物剂量
- 度拉糖肽1.5 mg,每周一次皮下注射;对照为安慰剂;中位随访5.4年(IQR 5.1-5.9),至少每6个月随访一次结局。
- 尿白蛋白与肌酐比值和估算肾小球滤过率由当地实验室检测的尿液与血清值每12个月评估一次。
研究设计与关键结果
- 多中心、随机、双盲、安慰剂对照试验,24个国家371个中心,纳入9901例,随机分为度拉糖肽组(n=4949)与安慰剂组(n=4952);中位随访5.4年(IQR 5.1-5.9),共51820人年;分析按意向治疗进行。
- 复合肾脏结局:度拉糖肽组848例(17.1%),发生率3.5/100人年;安慰剂组970例(19.6%),发生率4.1/100人年;HR 0.85(95%CI 0.77-0.93;p=0.0004)。
- 新发大量白蛋白尿:HR 0.77(95%CI 0.68-0.87;p<0.0001)。
- 估算肾小球滤过率持续下降≥30%:HR 0.89(95%CI 0.78-1.01;p=0.066)。
- 慢性肾脏替代治疗:HR 0.75(95%CI 0.39-1.44;p=0.39)。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验的探索性分析(REWIND);试验注册号NCT01394952;由Eli Lilly and Company资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在2型糖尿病合并心血管病史或心血管危险因素的人群中,长期使用度拉糖肽与复合肾脏结局减少相关;该结果为探索性分析,主要驱动来自新发大量白蛋白尿。
- 对估算肾小球滤过率持续下降≥30%(p=0.066)与慢性肾脏替代治疗(p=0.39)的效应未达统计学显著,床旁解读时不宜将复合结局的获益等同于上述单项终点获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analysis of the REWIND trial of the effect of dulaglutide on cardiovascular disease.
METHODS: REWIND was a multicentre, randomised, double-blind, placebo-controlled trial at 371 sites in 24 countries. Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1·5 mg) or placebo and followed up at least every 6 months for outcomes. Urinary albumin-to-creatinine ratios (UACRs) and estimated glomerular filtration rates (eGFRs) were estimated from urine and serum values measured in local laboratories every 12 months. The primary outcome (first occurrence of the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes), secondary outcomes (including a composite microvascular outcome), and safety outcomes of this trial have been reported elsewhere. In this exploratory analysis, we investigate the renal component of the composite microvascular outcome, defined as the first occurrence of new macroalbuminuria (UACR >33·9 mg/mmol), a sustained decline in eGFR of 30% or more from baseline, or chronic renal replacement therapy. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01394952.
FINDINGS: Between Aug 18, 2011, and Aug 14, 2013, 9901 participants were enrolled and randomly assigned to receive dulaglutide (n=4949) or placebo (n=4952). At baseline, 791 (7·9%) had macroalbuminuria and mean eGFR was 76·9 mL/min per 1·73 m2 (SD 22·7). During a median follow-up of 5·4 years (IQR 5·1-5·9) comprising 51 820 person-years, the renal outcome developed in 848 (17·1%) participants at an incidence rate of 3·5 per 100 person-years in the dulaglutide group and in 970 (19·6%) participants at an incidence rate of 4·1 per 100 person-years in the placebo group (hazard ratio [HR] 0·85, 95% CI 0·77-0·93; p=0·0004). The clearest effect was for new macroalbuminuria (HR 0·77, 95% CI 0·68-0·87; p<0·0001), with HRs of 0·89 (0·78-1·01; p=0·066) for sustained decline in eGFR of 30% or more and 0·75 (0·39-1·44; p=0·39) for chronic renal replacement therapy.
INTERPRETATION: Long-term use of dulaglutide was associated with reduced composite renal outcomes in people with type 2 diabetes.
FUNDING: Eli Lilly and Company.
参考来源
- Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019. PMID: 31189509. doi:10.1016/S0140-6736(19)31150-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。